Financial incentives to support diabetes care in teens with type 1 diabetes
Tests whether money rewards help teens with type 1 diabetes manage their care.
Key facts
- Who runs it
- Harvard Pilgrim Health Care
- Where
- Seattle, United StatesSee the site
- Trial code
- Registry title
- InvesT1D: Promoting Adolescent Investment in Diabetes Care
- Status
- Recruiting
- People taking part
- 96 people, planned
- Started
- 25 Jun 2024
- Expected to end
- 31 Oct 2027
- Type of study
- Interventional, 6 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Financial Incentives Program
- Record updated
- 16 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for teenagers with type 1 diabetes who use a continuous glucose monitor but do not use it all the time or take mealtime insulin often. A caregiver must also take part.
- Age
- 12 years and older (the record gives no upper age limit)
- Sex
- All sexes can join.
- Disease stage
- Type 1 diabetes diagnosed for 12 months or longer.
- Earlier treatment
- Must already use a continuous glucose monitor (CGM) for diabetes care. Must use diabetes technology that tracks bolus insulin doses if they want to work on bolus insulin.
- Biomarker or test result
- Average daily CGM use of 70% of the time or less, and/or an average of 3 or fewer bolus insulin doses a day.
Main reasons for not taking part
- Average CGM wear above 70% of the time, or more than 3 bolus insulin doses a day on average
- Severe other long-term health conditions that strongly affect daily diabetes care or health
- Adolescent is a ward of the state
- Cannot take part because of cognitive or physical reasons
- Caregiver not willing to take part and complete surveys
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Diagnosed with type 1 diabetes ≥12 months
- Utilize a continuous glucose monitor (CGM) to support diabetes management
- Average daily CGM use is less than or equal to 70% of the time and/or their baseline average insulin bolus administration is less than or equal to 3 times a day
- Are using diabetes technology that allows for tracking of bolus insulin administration if participant wants to work on improving daily bolus insulin administration
- Cognitively able to participate in incentive program and complete surveys
- Have access to a mobile phone to receive information about goal attainment and incentive updates
- Have the ability to upload glucose and insulin administration data remotely per processes used by participant's diabetes care team
- Caregivers are willing to participate in study and complete surveys
Who cannot take part
- Adolescent is not interested in using diabetes technology that allows for tracking of bolus insulin administration if participant wants to work on improving daily bolus insulin administration
- Severe comorbidities including other major chronic health conditions that significantly impact daily management demands or health outcomes
- At time of screening, average CGM wear is greater than 70% of the time or baseline average insulin bolus administration is greater than 3 times a day
- Cognitively or physically unable to participate
- Adolescent is a ward of the state
- Caregivers are not willing to participate in study and complete surveys
Where in United States
- Seattle Children'sSeattle, United StatesContact: Ciara A DeGraff, BATaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to see if a financial incentives program called InvesT1D is helpful to support diabetes management in adolescents with type 1 diabetes.
Read full original descriptionShow less
Adolescent participants will be randomized to usual care or receive financial incentives for meeting diabetes self-management and clinical outcomes goals during the study. Researchers will compare changes in glucose levels, as well as adolescent and caregiver person-reported outcomes between groups.
The 6 groups in the trial
- Group A (low-value incentive, 6 months [24 weeks])Treatment being tested
If the participant is assigned to Group A, they would receive $1.75 for each day that they meet their diabetes self-management goal. This equates to up to $49 every 4 weeks ($1.75 x 28 days = $49), or up to $294 over a period of 24 weeks. They would also receive $2.75 for each week that they meet their clinical outcome goal. This equates to up to $11 every 4 weeks ($2.75 x 4 weeks), or up to $66 over a period of 24 weeks. In total, they could earn up to $60 ($49 + $11) every 4 weeks, or up to $360 over a period of 24 weeks.
Treatment: Financial Incentives Program
- Group B (high-value incentive, 6 months [24 weeks])Treatment being tested
If the participant is assigned to Group B, they would receive $3.50 for each day that they meet their diabetes self-management goal. This equates to up to $98 every 4 weeks ($3.50 x 28 days = $98), or up to $588 over a period of 24 weeks. They would also receive $5.50 for each week that they meet their clinical outcome goal. This equates to up to $22 every 4 weeks ($5.50 x 4 weeks), or up to $132 over a period of 24 weeks. In total, they could earn up to $120 ($98 + $22) every 4 weeks, or up to $720 over a period of 24 weeks.
Treatment: Financial Incentives Program
- Group C (low-value incentive, 12 months [48 weeks])Treatment being tested
If the participant is assigned to Group C, they would receive $1.75 for each day that they meet their diabetes self-management goal. This equates to up to $49 every 4 weeks ($1.75 x 28 days = $49), or up to $588 over a period of 48 weeks. They would also receive $2.75 for each week that they meet their clinical outcome goal. This equates to up to $11 every 4 weeks ($2.75 x 4 weeks), or up to $132 over a period of 48 weeks. In total, they could earn up to $60 ($49 + $11) every 4 weeks, or up to $720 over a period of 48 weeks.
Treatment: Financial Incentives Program
- Group D (high-value incentive, 12 months [48 weeks])Treatment being tested
If the participant is assigned to Group C, they would receive $1.75 for each day that they meet their diabetes self-management goal. This equates to up to $49 every 4 weeks ($1.75 x 28 days = $49), or up to $588 over a period of 48 weeks. They would also receive $2.75 for each week that they meet their clinical outcome goal. This equates to up to $11 every 4 weeks ($2.75 x 4 weeks), or up to $132 over a period of 48 weeks. In total, they could earn up to $60 ($49 + $11) every 4 weeks, or up to $720 over a period of 48 weeks.
Treatment: Financial Incentives Program
- Group E (usual care, 6 months [24 weeks])No study treatment, for comparison
Usual care reflects the standard treatment currently provided to adolescents with type 1 diabetes at Seattle Children's Hospital. All adolescent participants in the study will have access to the multidisciplinary care team including a diabetes provider, registered diabetes nurse, social worker, and nutritionist. They will continue to be offered routine diabetes clinic appointments as is the standard of care. Telephone consultations are available 24/7 as often as necessary between clinic visits.
- Group F (usual care, 12 months [48 weeks])No study treatment, for comparison
Usual care reflects the standard treatment currently provided to adolescents with type 1 diabetes at Seattle Children's Hospital. All adolescent participants in the study will have access to the multidisciplinary care team including a diabetes provider, registered diabetes nurse, social worker, and nutritionist. They will continue to be offered routine diabetes clinic appointments as is the standard of care. Telephone consultations are available 24/7 as often as necessary between clinic visits.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- InvesT1D: Promoting Adolescent Investment in Diabetes Care
- Plain-language title
- Financial incentives to support diabetes care in teens with type 1 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 16 December 2025